Cardiff Other Operating Expenses vs Ebitda Analysis

CRDF Stock  USD 3.78  1.34  54.92%   
Cardiff Oncology financial indicator trend analysis is way more than just evaluating Cardiff Oncology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiff Oncology is a good investment. Please check the relationship between Cardiff Oncology Other Operating Expenses and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

Other Operating Expenses vs Ebitda

Other Operating Expenses vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiff Oncology Other Operating Expenses account and Ebitda. At this time, the significance of the direction appears to have pay attention.
The correlation between Cardiff Oncology's Other Operating Expenses and Ebitda is -0.99. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Ebitda in the same time period over historical financial statements of Cardiff Oncology, assuming nothing else is changed. The correlation between historical values of Cardiff Oncology's Other Operating Expenses and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Cardiff Oncology are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Other Operating Expenses i.e., Cardiff Oncology's Other Operating Expenses and Ebitda go up and down completely randomly.

Correlation Coefficient

-0.99
Relationship DirectionNegative 
Relationship StrengthSignificant

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cardiff Oncology. It is also known as Cardiff Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Ebitda

Most indicators from Cardiff Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiff Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.The current Selling General Administrative is estimated to decrease to about 7.5 M. The current Issuance Of Capital Stock is estimated to decrease to about 16.3 M
 2021 2022 2023 2024 (projected)
Interest Income264K1.6M3.8M4.0M
Cost Of Revenue500K200K32.9M34.5M

Cardiff Oncology fundamental ratios Correlations

0.99-0.540.541.00.650.771.0-0.280.050.540.670.57-0.630.480.56-0.10.78-0.120.830.160.390.14-0.260.450.85
0.99-0.530.50.990.690.770.99-0.2-0.080.510.60.5-0.640.420.48-0.170.8-0.260.850.020.350.06-0.180.450.87
-0.54-0.53-0.98-0.56-0.07-0.31-0.550.2-0.06-0.19-0.280.00.19-0.090.00.57-0.110.02-0.09-0.10.02-0.150.25-0.23-0.42
0.540.5-0.980.560.030.280.55-0.230.250.20.360.08-0.160.160.09-0.50.070.150.070.270.010.29-0.320.220.38
1.00.99-0.560.560.640.761.0-0.280.050.520.650.54-0.610.480.52-0.130.76-0.120.820.160.370.14-0.270.430.85
0.650.69-0.070.030.640.850.650.0-0.30.80.570.43-0.830.480.460.290.74-0.490.76-0.110.72-0.070.050.440.9
0.770.77-0.310.280.760.850.76-0.4-0.170.890.680.63-0.970.430.630.110.75-0.410.810.00.77-0.030.110.680.87
1.00.99-0.550.551.00.650.76-0.280.040.530.650.55-0.620.480.53-0.120.77-0.130.830.150.370.13-0.260.440.86
-0.28-0.20.2-0.23-0.280.0-0.4-0.28-0.11-0.34-0.18-0.370.36-0.16-0.38-0.09-0.25-0.18-0.23-0.25-0.290.150.12-0.22-0.17
0.05-0.08-0.060.250.05-0.3-0.170.04-0.110.00.420.390.20.380.40.29-0.250.9-0.130.940.110.77-0.4-0.03-0.2
0.540.51-0.190.20.520.80.890.53-0.340.00.730.62-0.910.440.660.330.49-0.220.550.20.920.050.070.580.75
0.670.6-0.280.360.650.570.680.65-0.180.420.730.82-0.680.570.840.260.450.120.580.520.730.55-0.080.610.6
0.570.50.00.080.540.430.630.55-0.370.390.620.82-0.640.340.980.420.520.160.680.480.70.41-0.060.670.42
-0.63-0.640.19-0.16-0.61-0.83-0.97-0.620.360.2-0.91-0.68-0.64-0.4-0.64-0.17-0.680.46-0.740.04-0.810.05-0.25-0.72-0.77
0.480.42-0.090.160.480.480.430.48-0.160.380.440.570.34-0.40.450.340.410.250.460.460.370.2-0.290.010.45
0.560.480.00.090.520.460.630.53-0.380.40.660.840.98-0.640.450.520.540.210.660.530.720.37-0.160.590.43
-0.1-0.170.57-0.5-0.130.290.11-0.12-0.090.290.330.260.42-0.170.340.520.110.320.140.440.570.19-0.29-0.050.06
0.780.8-0.110.070.760.740.750.77-0.25-0.250.490.450.52-0.680.410.540.11-0.370.95-0.130.36-0.160.010.450.71
-0.12-0.260.020.15-0.12-0.49-0.41-0.13-0.180.9-0.220.120.160.460.250.210.32-0.37-0.330.89-0.10.55-0.6-0.31-0.37
0.830.85-0.090.070.820.760.810.83-0.23-0.130.550.580.68-0.740.460.660.140.95-0.33-0.040.46-0.020.030.540.74
0.160.02-0.10.270.16-0.110.00.15-0.250.940.20.520.480.040.460.530.44-0.130.89-0.040.320.7-0.550.01-0.01
0.390.350.020.010.370.720.770.37-0.290.110.920.730.7-0.810.370.720.570.36-0.10.460.320.230.010.570.63
0.140.06-0.150.290.14-0.07-0.030.130.150.770.050.550.410.050.20.370.19-0.160.55-0.020.70.23-0.190.260.0
-0.26-0.180.25-0.32-0.270.050.11-0.260.12-0.40.07-0.08-0.06-0.25-0.29-0.16-0.290.01-0.60.03-0.550.01-0.190.45-0.13
0.450.45-0.230.220.430.440.680.44-0.22-0.030.580.610.67-0.720.010.59-0.050.45-0.310.540.010.570.260.450.47
0.850.87-0.420.380.850.90.870.86-0.17-0.20.750.60.42-0.770.450.430.060.71-0.370.74-0.010.630.0-0.130.47
Click cells to compare fundamentals

Cardiff Oncology Account Relationship Matchups

Cardiff Oncology fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets13.1M134.7M149.5M116.2M81.6M45.3M
Total Stockholder Equity7.3M128.2M140.4M106.3M69.7M36.9M
Net Debt(8.5M)(130.1M)(8.8M)(13.6M)(19.5M)(20.5M)
Cash10.2M131.0M11.9M16.3M21.7M24.3M
Cash And Short Term Investments10.2M131.0M140.8M105.3M74.8M41.8M
Common Stock Shares Outstanding6.0M20.9M39.0M43.6M44.7M46.9M
Liabilities And Stockholders Equity13.1M134.7M149.5M116.2M81.6M45.3M
Other Stockholder Equity217.2M359.6M400.4M404.8M409.3M429.8M
Total Current Assets11.4M133.4M146.1M111.3M77.4M43.3M
Common Stock7.7K8.3K3.7K4K3.6K3.4K
Other Current Liab3.3M3.9M4.0M4.5M7.1M7.4M
Total Current Liabilities4.8M6.1M6.6M7.8M10.4M5.4M
Property Plant And Equipment Net1.6M966.7K3.2M3.5M2.9M1.8M
Retained Earnings(208.9M)(231.5M)(259.8M)(298.1M)(339.5M)(322.6M)
Accounts Payable656K1.4M1.4M2.0M2.0M1.3M
Non Current Assets Total1.7M1.4M3.4M4.9M4.2M2.3M
Non Currrent Assets Other103K(813.7K)(1.8M)1.4M1.3M1.3M
Net Receivables204K320.5K535K771K288K225.2K
Non Current Liabilities Total994K450.5K2.6M2.0M1.5M1.4M
Other Current Assets955K2.1M4.8M5.2M2.3M1.5M
Total Liab5.8M6.6M9.1M9.8M11.9M11.2M
Property Plant And Equipment Gross1.6M966.7K3.2M3.5M6.7M7.0M
Accumulated Other Comprehensive Income(971.7K)(2.2M)(142K)(395K)(67K)(70.4K)
Common Stock Total Equity7.7K8.3K3.7K4K4.6K4.7K
Net Tangible Assets7.3M128.2M140.4M106.3M122.3M128.4M
Retained Earnings Total Equity(208.9M)(231.5M)(259.8M)(298.1M)(268.3M)(281.7M)
Capital Surpluse217.2M361.8M400.5M404.8M465.6M249.6M
Deferred Long Term Liab1.8M1.1M4.1K285.0K256.5K243.7K
Property Plant Equipment877.8K623.7K382K1.3M1.1M1.2M
Other Assets157.6K404.2K239K1.4M1.00.95
Other Liab1.8M1.2M132.5K441.2K397.1K377.3K
Net Invested Capital7.3M128.2M140.4M106.3M69.7M73.8M
Net Working Capital6.6M127.2M139.6M103.5M67.0M72.2M

Currently Active Assets on Macroaxis

When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.95)
Revenue Per Share
0.015
Quarterly Revenue Growth
0.17
Return On Assets
(0.38)
Return On Equity
(0.68)
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.